Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HNRNPLL antisense RNA 1 (HNRNPLL-AS1) is a putative antisense long non-coding RNA transcribed from the HNRNPLL locus. As of September 2025, there is no experimental characterization, biological function, disease association, or recognition as a therapeutic target in the literature or major genomic databases. Antisense lncRNAs in general can regulate their sense counterparts through mechanisms like mRNA stability modulation, RNA-RNA interaction, or alternative splicing, but such functions have not been attributed to HNRNPLL-AS1[5]. There is a well-characterized protein-coding gene, HNRNPLL, which encodes a splicing factor involved in immune cell differentiation[2], but no antisense RNA for this locus has been functionally described.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HNRNPLL antisense RNA 1 (HNRNPLL-AS1).